Intergovernmental cooperation between the United States and China was an important part of the fight against Severe Acute Respiratory Syndrome (SARS) in 2003. Yet serious collaboration to combat COVID-19 is yet to materialise. The state of US–China bilateral relations and the failure to cooperate has arguably worsened the pandemic.

Americans are typically good about getting their children the standard roster of shots. They take kids in for check-ups during the first years of life and, with these check-ups, come vaccines. However, as these children age, compliance decreases. In adulthood, Americans fail to get booster shots and chronically skip the annual flu vaccine.

InSilicoTrials.com is the only cloud-based platform that offers complex computational models made easy-to-use and cost-effective for the benefit of all pharmaceutical companies and medical device producers. InSilicoTrials recently won 3 projects (SimCardioTest, Brainteaser, In SilicoWorld) out of 9 submitted to Horizon 2020, EU’s most important funding program for research and innovation: an amazing result since usually the acceptance rate is 5%.

IoT systems were regarded as offering potentially helpful functionality in mediating the action plans developed with a trusted clinician, but technologically adept participants were not yet ready to trust artificial intelligence to generate novel advice. Research is needed to ensure that technological capability does not outstrip the trust of the individuals using it.

SGD Pharma is continuing the expansion of its Ready-to-Use (RTU) Sterinity molded glass vial platform with the introduction of an amber glass 50ml volume option in Tray, now available ex-stock.
The vials, developed at industrial scale, allow global pharmaceutical companies to accelerate the time-to-market of their high-value parenteral drugs with RTU primary packaging.

Accidental medical errors, specifically related to drug delivery and toxicity-related events, are the third largest cause of death among Americans, according to CNBC. More than 131 million adult Americans are making some sort of prescription medication in the form of an ingestible. Over 11.8 million people worldwide use an injectable device to deliver their medication daily. Now, the two devices that were mentioned, ingestible pills and the syringe needle used to inject medication, were invented in 1500 BCE and 1853 respectively. These forms of pharmacology delivery have not had dramatic changes since their inception into the world of medication. Even when taking into consideration medical safety, the largest changes in the form that these devices take have come from the inversion of the needle following injection and the “controlled-release” of medication from the pill form.

The microbiome is the vast collection of bacteria in the human gut. It is estimated that each person carries around 100 trillion bacterial cells in their digestive tract, belonging to several thousand species. These are believed to be involved in the development of chronic inflammatory intestinal diseases, to trigger diabetes, to be responsible for obesity, even neurological diseases such as multiple sclerosis and Parkinson's could have their causes here—not to mention depressions and autistic disorders.

CD8+ T cells are immune system foot soldiers that specifically kill cells that, if left unchecked, would be dangerous for the body. One of their prime targets is cancer cells, but unfortunately the disease has a few ways to avoid detection. CAR T cell immunotherapy involves extracting these T cells from a patient, tweaking them to better target tumors, then returning them to the body to get to work.

Researchers at Chalmers University of Technology in Sweden and collaborators created a technique to produce fluorescently labeled mRNA, allowing them to track its entry and distribution into cells. Using such molecules could help scientists develop better ways to deliver mRNA therapeutics into the body, potentially playing a vital role in the new wave of mRNA therapies, including vaccines.

A recent study by scientists from Japanese universities has shown that the shape of cell-derived nanoparticles, known as "extracellular vesicles" (EVs), in body fluids could be a biomarker for identifying types of cancer. In the study, the scientists successfully measured the shape distributions of EVs derived from liver, breast, and colorectal cancer cells, showing that the shape distributions differ from one another.

The COVID vaccines currently being deployed were developed with unprecedented speed, but the mRNA technology at work in some of them is an equally impressive success story. Because any desired mRNA sequence can be synthesized in massive quantities, one of the biggest hurdles in a variety of mRNA therapies is the ability to package those sequences into the lipid nanoparticles that deliver them into cells.

We need to embrace principles from the tech industry and incorporate lessons learned from the pandemic to address the challenges of R&D productivity in pharma.

Despite mounting court and legislative scrutiny of pharmacy and prescription benefit manager practices, Amazon has chosen to throw its hat into the discount pharmacy ring. Could Amazon "disrupt" prescription drug delivery?

The modified "natural killer" cells can differentiate between cancer cells and healthy cells that are often intermingled in and around tumors, destroying only the targeted cells. The natural killer cells' ability to distinguish the target cells, even from healthy cells that bear similar markers, brings new promise to this branch of immunotherapy, say members of the research team behind a paper published in the current issue of the journal iScience, newly posted on the PubMed database.

Caribou is developing all three programs for patients with blood cancers whose disease has come back despite undergoing other treatments or did not respond to those treatments in the first place. The company's most advanced program, CB-010, is an anti-CD19 CAR-T that’s in a phase 1 trial in B-cell non-Hodgkin lymphoma. Some of the IPO proceeds will support this trial through initial data, which are expected in 2022, according to a securities filing.

The health care industry is starting to adopt digital twins to improve personalized medicine, health care organization performance, and new medicines and devices. Although simulations have been around for some time, today’s medical digital twins represent an important new take. These digital twins can create useful models based on information from wearable devices, omics, and patient records to connect the dots across processes that span patients, doctors, and health care organizations, as well as drug and device manufacturers.

Walmart has announced a new private brand of analog insulin, the first of its kind, designed to overcome common impediments, like affordability of and access to diabetes care, especially for those without health insurance, according to a Tuesday press release shared on the company's official website. The new plan went into effect this week, and includes FexPen, which goes for $85.88, and analog insulin vials, sold at $72.88. Both products are only available through Walmart's proprietary ReliOn brand, and could save customers up to $101 per vial or $251 per package of FlexPens — a savings of 58% to 75% — read the press release.

The American healthcare system is so uniquely terrible among developed countries that a localisation team translating a recent indie game had to completely replace a line about crowdfunding an emergency medical procedure because it wouldn’t make sense to players outside of the United States.
Cozy Grove, which launched back in April, is a wonderful little simulation game about setting up camp on a charming, haunted island. At some point, one of the several ghosts that you can meet over the course of the game underlines the importance of making friends with a scary hypothetical: “What if you get sick and need to crowdfund your appendectomy?!”

The new therapy, called ALETA-001, aims to boost a treatment called CAR T-cell therapy, which takes some of a patient's immune cells and alters them to attack cancer.

A study involving virtual rather than real patients was as effective as traditional clinical trials in evaluating a medical device used to treat brain aneurysms, according to new research. The findings are proof of concept for what are called in-silico trials, where instead of recruiting people to a real-life clinical trial, researchers build digital simulations of patient groups, loosely akin to the way virtual populations are built in various computer games.

Alzheimer's is an irreversible, progressive brain disorder that over time destroys memory and thinking skills, and in the end, the ability to carry out everyday tasks, explains the Food and Drug Administration (FDA). Changes in the brain of amyloid plaques and neurofibrillary, or tau, tangles lead to a loss of neurons and their connections, which in turn affect a person's ability to remember and to think. Its cause is still not fully known. A number of different methods for reversing or slowing down Alzheimer's are being developed, including a potential vaccine against the brain disorder that just showed positive results during its Phase II clinical trial: AADvac1.

The treatment known as CAR-T, in which white blood cells are genetically modified to attack blood cancer, is one of the most exciting and expensive in medicine. But it has not been directly compared to standard treatments in a randomized trial — until now. Bristol Myers Squibb said Thursday that its CAR-T, Breyanzi, prevented the return of large B-cell lymphoma better than the standard of care treatment, which includes a chemotherapy regimen and a stem cell transplant, in which bone marrow cells are replaced to try to cure blood cancer.

Global pharma major Lupin Limited (Lupin) on Monday announced the launch of its Digital Asthma Educator platform for guiding patients on the correct technique of using inhalers. The educator platform has been launched as a part of the company's long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailments.

In 2015, Götz and his colleagues published an initial study that saw ultrasound waves successfully remove beta-amyloid from the brains of mice. Beta-amyloids are a special class of proteins linked to several symptoms in people with Alzheimer's, including dementia and cognitive decline. And the researchers found that scans of the brain in ultrasound help to break up beta-amyloid, reversing the process of neurological damage caused by the amyloids.

The VISTA's Select suite of exclusive services allows your health system to systematically manage the above obstacles and uncover costs often unknown to the hospital's leadership team.  Fill out the form to download and learn more about how CFO's can contain costs, and by partnering with VISTA, they can reduce overall labor costs, centralize and standardize reporting and vendor management.

Amongst other variants, the woman was reported to have had the E484K mutation, which is part of the Alpha variant (B.1.1.7, which was first seen in the UK) and the N510Y mutation, which is part of the Beta variant (B.1.351, which was first seen in South Africa). In total, the virus was reported to have undergone 13 mutations to the spike protein and 19 others that could change its behavior.

Global glass primary packaging supplier SGD Pharma has expanded its ready-to-use (RTU) molded glass vial range to introduce a market-first 50ml volume option in tray developed at industrial scale by a molded glass manufacturer. The Sterinity platform, which includes both ISO and EasyLyo injectable vials, offers high quality sterile Type I molded glass to speed up aseptic filling processes and reduce time to market for high value parenteral drugs.

We’re used to the idea of wearable technology measuring everything from our temperature and heart rate, to blood glucose levels and sleep. But what if we moved those devices inside the body? That’s what Swedish startup DSRuptive does, using small glass capsules — the size of a grain of rice.
On Wednesday, the company announced the results of the first clinical study showing the effectiveness of injectable implants in monitoring body temperature.
The results are a glimpse into a future when implants could be the norm for everything, from health monitoring to payments and identification.